Innova Captab reported a strong Q3 FY26, with revenue from operations surging to ₹450 crore, a 42% year-on-year increase. 9M FY26 revenue reached ₹1,182 crore, up 27% year-on-year. The CDMO business grew by 29%, and branded generics surged by 79%. EBITDA for Q3 FY26 climbed to ₹71.1 crore, a 39.6% increase, and PAT stood at ₹42.1 crore.
Financial Performance Highlights
In Q3 FY26, Innova Captab achieved consolidated revenue of ₹450.3 crore, reflecting a robust 42.3% year-on-year growth, fueled by strong demand in both the CDMO and branded generic segments. For the 9-month FY26 period, revenue reached ₹1,182.2 crore, up 27.3% year-on-year.
Exports accounted for 35% of Q3 FY26 revenue and 32% for 9M FY26.
EBITDA for Q3 FY26 increased to ₹71.1 crore from ₹50.9 crore in the previous year, marking a 39.6% year-on-year increase. For 9M FY26, EBITDA reached ₹183.7 crore, up 24.8% from ₹147.1 crore, with margins remaining steady at 15.8% for the quarter and 15.5% over nine months. PAT stood at ₹42.1 crore for Q3 FY26 and ₹102.8 crore for 9M FY26.
Business Segment Performance
The CDMO business reported revenue of ₹298.7 crore in Q3 FY26, a 29% increase from ₹231.6 crore in the previous year. For 9M FY26, CDMO revenue totaled ₹813.9 crore, reflecting an 18% year-on-year growth.
The Branded Generics segment demonstrated strong performance, with Q3 revenue reaching ₹151.6 crore, a surge of 79% year-on-year. For 9M FY26, this segment delivered ₹368.4 crore, a 56% increase.
Operational Developments
The company’s manufacturing capabilities were further strengthened by GMP certification, including UK-MHRA approval for the cephalosporin Baddi unit and PIC/S via SMDC Ukraine for all Jammu blocks. The Jammu facility reported revenue of ₹89 crores for the quarter.
Source: BSE
